Mean values at evaluation | Within 3 mo | 4–6 mo | 7–12 mo | 13–24 mo | >2 year | Total | P |
---|
|
---|
Age, years | 65.3 | 63.6 | 62.4 | 61.7 | 62.6 | 63.6 | 0.02 |
Disease duration, years | 6.9 | 7.1 | 7.3 | 7.7 | 8.9 | 7.3 | <0.001 |
SJC28 | 0.33 | 0.46 | 0.54 | 0.41 | 0.44 | 0.43 | 0.20 |
TJC28 | 0.55 | 0.74 | 0.89 | 0.50 | 0.62 | 0.68 | 0.06 |
ESR | 13.7 | 13.6 | 13.8 | 12.2 | 14.1 | 13.6 | 0.78 |
CRP | 4.8 | 4.8 | 4.7 | 4.1 | 5.2 | 4.8 | 0.87 |
InvGlobal VAS | 9.2 | 9.9 | 10 | 10 | 11 | 9.9 | 0.56 |
Patientglobal VAS | 31 | 29 | 27 | 29 | 30 | 29 | 0.31 |
Pain VAS | 28 | 27 | 27 | 30 | 27 | 28 | 0.82 |
HAQ 0-3 | 0.64 | 0.63 | 0.65 | 0.65 | 0.73 | 0.65 | 0.62 |
DAS28 0-9.4 | 2.2 | 2.2 | 2.3 | 2.2 | 2.3 | 2.2 | 0.77 |
DAS28 remission <2.6 | 68% | 67% | 65% | 67% | 66% | 66% | 0.91 |
THERAPY NOW | | | | | | | |
MTX, mono or combo | 64% | 68% | 61% | 70% | 61% | 64% | 0.13 |
MTX combo + any DMARD | 38% | 41% | 40% | 43% | 31% | 39% | 0.15 |
Prednisolon | 37% | 44% | 42% | 37% | 37% | 40% | 0.11 |
Biologic (+−DMARDs) | 8.5% | 8.5% | 11% | 13% | 9.3% | 9.6% | 0.33 |
Without DMARDs | 16% | 13% | 17% | 12% | 18% | 15% | 0.31 |